SALT LAKE CITY, Nov. 17, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today ...
Combination of the immunocytokine F16-IL2 with doxorubicin or paclitaxel in patients with solid tumors: Results from two phase Ib trials. This is an ASCO Meeting Abstract from the 2011 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results